Amicus Therapeutics Executives Sell Shares
Several executives at Amicus Therapeutics, including Ellen Rosenberg, Bradley L. Campbell, David Michael Clark, and Jeff Castelli, have sold shares of the company according to SEC Form 4 filings. The sales, executed under Rule 10b5-1 trading plans, totaled approximately $2.14 million. The transactions occurred in late November 2025, with the executives selling shares at prices ranging from $10.00 to $10.31 per share.
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Rosenberg Ellen | Chief Legal Officer, 10% Owner | Sell | $958,478 | Form 4 |
| Campbell Bradley L | President and CEO, 10% Owner | Sell | $146,522 | Form 4 |
| Clark David Michael | Chief People Officer, 10% Owner | Sell | $258,932 | Form 4 |
| Castelli Jeff | Chief Development Officer, 10% Owner | Sell | $773,658 | Form 4 |
Several executives at Amicus Therapeutics have recently sold shares of the company, according to SEC Form 4 filings.
Ellen Rosenberg, Chief Legal Officer and 10% Owner, sold 95,621 shares over three transactions on November 24, 25, and 26, 2025, for a total of $958,478, at prices ranging from $10.00 to $10.31, with a weighted average price noted for the first transaction. Following these sales, Rosenberg directly owns 507,710 shares and indirectly owns 15,000 shares through a spouse. These transactions were executed under a Rule 10b5-1 trading plan established on September 10, 2024.
Bradley L. Campbell, President and CEO and a 10% owner, sold 14,587 shares on November 24, 2025, at a weighted average price of $10.0447 per share, totaling $146,522. Campbell now directly owns 1,137,282 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
David Michael Clark, Chief People Officer and Director, sold 25,643 shares on November 24, 2025, at a weighted average price of $10.0976 per share, totaling $258,932. Post-transaction, Clark directly owns 296,975 shares. The sale was conducted under a Rule 10b5-1 trading plan established on March 14, 2025.
Jeff Castelli, Chief Development Officer and 10% owner, sold 76,158 shares on November 24, 2025, at a weighted average price of $10.1586, totaling $773,658. Following the sale, Castelli directly owns 439,318 shares of Amicus Therapeutics.
